A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma

Autores
Categoría Estudio primario
Registro de estudiosclinicaltrials.gov
Año 2015
This is a multicenter, open-label, stratified, randomized study to evaluate the safety, tolerability, antitumor activity, pharmacokinetics, pharmacodynamics, and immunogenicity of durvalumab or tremelimumab monotherapy, or durvalumab in combination with tremelimumab or bevacizumab in advanced hepatocellular carcinoma.
Epistemonikos ID: 4ac78306cf40f1c5d08f7f1111ad9c2c513cabdb
First added on: May 12, 2024